Breast cancers are highly heterogeneous at both the cellular and molecular levels and are classified clinically by immunohistochemistry and/or in situ hybridization-based detection of estrogen receptor-α (ER-α), progesterone receptor (PR), and HER2/ErbB-2 expression [3,4,5]. Here, ESR1 is linked to breast carcinoma.